You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stryker (SYK) Reports Q1 Earnings: What Key Metrics Have to Say
Read MoreHide Full Article
For the quarter ended March 2025, Stryker (SYK - Free Report) reported revenue of $5.87 billion, up 11.9% over the same period last year. EPS came in at $2.84, compared to $2.50 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $5.7 billion, representing a surprise of +2.88%. The company delivered an EPS surprise of +4.03%, with the consensus EPS estimate being $2.73.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Stryker performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net Sales by Geography- United States: $4.44 billion versus $4.25 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +13.4% change.
Net Sales by Geography- International: $1.43 billion versus the four-analyst average estimate of $1.44 billion. The reported number represents a year-over-year change of +7.3%.
Net Sales by Geography- Orthopaedics- Trauma and Extremities- International: $232 million versus the three-analyst average estimate of $228.49 million. The reported number represents a year-over-year change of +5.9%.
Net Sales by Geography- Orthopaedics- International: $682 million compared to the $700 million average estimate based on three analysts. The reported number represents a change of +6.1% year over year.
Net Sales by Geography- Orthopaedics: $2.36 billion versus the seven-analyst average estimate of $2.31 billion. The reported number represents a year-over-year change of +5%.
Net Sales by Business- MedSurg and Neurotechnology: $3.51 billion versus $3.41 billion estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +17.1% change.
Net Sales by Geography- Orthopaedics- Knees: $639 million versus the five-analyst average estimate of $624.41 million. The reported number represents a year-over-year change of +8.7%.
Net Sales by Geography- Orthopaedics- Spinal Implants: $166 million compared to the $172.83 million average estimate based on five analysts. The reported number represents a change of -44.7% year over year.
Net Sales by Geography- Orthopaedics- Hips: $443 million versus $426.31 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +12.7% change.
Net Sales by Geography- Orthopaedics- Other: $162 million versus $184.38 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +21.8% change.
Net Sales by Geography- Orthopaedics- Trauma and Extremities: $945 million versus $902.89 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +13.9% change.
Net Sales by Business- MedSurg and Neurotechnology- Instruments: $730 million versus the five-analyst average estimate of $701.06 million. The reported number represents a year-over-year change of +9.5%.
Shares of Stryker have returned +1.6% over the past month versus the Zacks S&P 500 composite's -0.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Stryker (SYK) Reports Q1 Earnings: What Key Metrics Have to Say
For the quarter ended March 2025, Stryker (SYK - Free Report) reported revenue of $5.87 billion, up 11.9% over the same period last year. EPS came in at $2.84, compared to $2.50 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $5.7 billion, representing a surprise of +2.88%. The company delivered an EPS surprise of +4.03%, with the consensus EPS estimate being $2.73.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Stryker performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales by Geography- United States: $4.44 billion versus $4.25 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +13.4% change.
- Net Sales by Geography- International: $1.43 billion versus the four-analyst average estimate of $1.44 billion. The reported number represents a year-over-year change of +7.3%.
- Net Sales by Geography- Orthopaedics- Trauma and Extremities- International: $232 million versus the three-analyst average estimate of $228.49 million. The reported number represents a year-over-year change of +5.9%.
- Net Sales by Geography- Orthopaedics- International: $682 million compared to the $700 million average estimate based on three analysts. The reported number represents a change of +6.1% year over year.
- Net Sales by Geography- Orthopaedics: $2.36 billion versus the seven-analyst average estimate of $2.31 billion. The reported number represents a year-over-year change of +5%.
- Net Sales by Business- MedSurg and Neurotechnology: $3.51 billion versus $3.41 billion estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +17.1% change.
- Net Sales by Geography- Orthopaedics- Knees: $639 million versus the five-analyst average estimate of $624.41 million. The reported number represents a year-over-year change of +8.7%.
- Net Sales by Geography- Orthopaedics- Spinal Implants: $166 million compared to the $172.83 million average estimate based on five analysts. The reported number represents a change of -44.7% year over year.
- Net Sales by Geography- Orthopaedics- Hips: $443 million versus $426.31 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +12.7% change.
- Net Sales by Geography- Orthopaedics- Other: $162 million versus $184.38 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +21.8% change.
- Net Sales by Geography- Orthopaedics- Trauma and Extremities: $945 million versus $902.89 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +13.9% change.
- Net Sales by Business- MedSurg and Neurotechnology- Instruments: $730 million versus the five-analyst average estimate of $701.06 million. The reported number represents a year-over-year change of +9.5%.
View all Key Company Metrics for Stryker here>>>Shares of Stryker have returned +1.6% over the past month versus the Zacks S&P 500 composite's -0.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.